infohep news

• Access to medicines & diagnostics

  Cameroon study shows hepatitis C treatment is feasible, highly effective in sub-Saharan Africa

  Keith Alcorn / 23 June 2020

  High cure rates for hepatitis C can be achieved in Cameroon but the cost of treatment remains out of reach for all but the wealthiest, findings from a demonstration study of direct-acting antiviral ...

• Harm reduction interventions and policy

  Bacterial infection of the heart on the rise among people with hepatitis C in United States

  Keith Alcorn / 23 June 2020

  Diagnoses of infective endocarditis, a life-threatening bacterial infection of the heart valves, have become more common over the past ten years among people with hepatitis C and people with opioid use disorder ...

• Liver transplants

  NASH is fastest-growing reason for a liver transplant in United States

  Keith Alcorn / 22 June 2020

  Non-alcoholic steatohepatitis (NASH), the severe form of non-alcoholic fatty liver disease (NAFLD), is now the most common reason for a liver transplant in women, older patients and people receiving Medicare insurance in the ...

• Epidemiology

  Hepatitis C in England: deaths decline but new infections steady since 2011

  Keith Alcorn / 09 June 2020

  The number of people with chronic hepatitis C infection in England has fallen by 30% since 2016 due to direct-acting antiviral treatment, says Public Health England in a new report on the ...

• Coronavirus

  Non-alcoholic fatty liver disease does not raise the risk of COVID-19, gene study shows

  Keith Alcorn / 26 May 2020

  People with a genetic profile that strongly predicts non-alcoholic or metabolic-associated fatty liver disease were not at higher risk of being hospitalised with COVID-19 in the United Kingdom, an analysis of the ...